
这个市场不建议进入,结论是 NO。核心故事很简单:利润几乎被旧品牌 Revive Naturals 吃完了,新品牌没有任何真正跑出来的样本,整体更像是一个低利润、老品牌锁定的市场;你想靠单个 ASIN 切进去,钱够启动,但不够证明你能赢。
These products have successfully captured market share and are profitable. Their design and features are suggested for your investment, based on market competition, saturation, and demand.
Green indicates better success rate, red indicates poorer success rate. If you are a new brand, focus on the left side; if you are an old brand, focus on the right side.
这个市场不适合现在进入,结论是 NO。 现有数据几乎只有 Revive Naturals 这一类旧品牌在吃利润,新品牌新上架产品的可盈利率为 0%,而且市场里没有看到任何真正的新品牌成功样本;这说明不是“能不能做”,而是“基本被旧品牌和品牌力锁死了”。
钱够不够:能做单个 ASIN 的入场,但不够证明你能赢。 你的预算是 500,000 CNY,折合约数万英镑级别,明显高于当前已识别的该品牌单品早期投入门槛;但市场里最赚钱的样本是 Revive Naturals 的 B084YY2KXB,售价 £14.78,月销 2,000,月营收约 £29,560,利润率 10.44%,而且它属于旧品牌老款,不是新卖家可直接复制的成功模型。更关键的是,数据里没有任何新品牌新上架的盈利案例,意味着你即使能承担前几个月的采购、物流和投放,也还要额外承受研发、品牌和认证成本,这些都不在 ASIN 预算里。
市场故事很清楚:这是一个旧品牌主导、可复制性差、对小卖家不友好的市场。 Revive Naturals 这类旧品牌靠复合配方、品牌势能和老链接持续放量,B084YY2KXB 的卖点是“五种胶原蛋白来源+透明质酸+维生素C+生物素”,但这套打法更像大品牌资源堆出来的结果,不是小业务轻量切入的机会。现在没有可作为“小卖家成功案例”的真实样本,也没有足够的新品牌盈利率支撑你判断市场可进;因此,对小卖家来说这不是机会市场,对大品牌来说也只能算“可以砸钱硬进”,但不是高胜率市场。
关键结论:不要推进。 参考标杆只能看 Revive Naturals 的 B084YY2KXB;小卖家没有可跟随的真实成功 ASIN。
Alternative solutions may pose a risk to your investment in certain markets.
这个市场不值得进入:只有1个可验证的盈利ASIN,利润率仅10.4%,已经接近底线,而且新品牌没有任何可验证的成功案例,整体更像是被老品牌把持的低利润市场。 对大品牌来说也不是好机会,因为这类市场要么靠长期资源和品牌力吃份额,要么就会陷入价格战;对小品牌来说更不成立,因为看不到<300评论的真实成功样本,反而有明显的高门槛信号。
这个市场不适合进入:当前可识别数据几乎只有 Revive Naturals 这一条样本,且它是老品牌、旧品类中的成熟产品,利润率只有 10.4%,已经接近你定义的低利润/价格战区间。更关键的是,新品可识别盈利率为 0%,没有任何证据表明小品牌能在不靠激进手段的情况下稳定跑通。
All products profit ratio distribution, including all products. For products with insufficient sales or missing profit ratio data, they will be categorized into other rows. This distribution included products that cannot determine the release date.
Most profitable products ranked by profit value. Only includes products with positive profitability and active sales, regardless of release date.
![]() | B084YY2KXB | Revive Naturals | 2018-10-21 | Yes | £14.78 | 2000pcs | £29560.0 | 10.44% | £3086.07 |
这不是一个适合新品牌进入的市场:核心盈利几乎完全被老品牌占住,且新品牌新品盈利数据为空,说明真正的新进入者基本没有跑出来。 对小商家来说,这个市场不可直接进入;对大品牌来说,理论上还能进,但必须带着强品牌力和高预算,否则大概率被卷死。
这个市场不适合进入,结论很明确:当前样本里只有 1 个可分析产品,且全部利润都集中在 Revive Naturals 的老品 B084YY2KXB,利润率只有 10.4%,已经落在价格战/低利润区间边缘。 这不是一个对新品牌友好的市场,更谈不上对小商家友好;要想复制这种结果,通常要么是老品牌做强品牌心智,要么要投入远超单个 ASIN 前期预算的资源。
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Y-axis is product counts. X-axis is time period. For each time period, there are 2 column, each column is a released type of a product. Columns are in following orders: New product, New product on old listing
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2022 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2024 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Header is the profit ratios and first column is different time period. Each cells includes how many products are relased at the specific timerange and has a corresponding profit ratios. Only profitable and with active sales (more than 100 pcs in 3 months) will be considered. Any products without sufficient sold units in 3 months will be marked as 'other'.
| Time/Profit% | x < -10.0% | -10.0% <= x < 0.0% | 0.0% <= x < 10.0% | 10.0% <= x < 20.0% | 20.0% <= x < 30.0% | 30.0% <= x < 40.0% | x >= 40.0% | other |
|---|---|---|---|---|---|---|---|---|
| 2025/7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2025/12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 2026/6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |